Mammary Cell News 11.08 March 7, 2019 | |
| |
TOP STORYEffective Breast Cancer Combination Therapy Targeting BACH1 and Mitochondrial Metabolism BTB and CNC homology1 (BACH1) decreased glucose utilization in the tricarboxylic acid cycle and negatively regulated transcription of electron transport chain (ETC) genes. BACH1 depletion by shRNA or degradation by hemin sensitized cells to ETC inhibitors such as metformin, suppressing growth of both cell line and patient-derived tumor xenografts. [Nature] Abstract | Press Release | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Phase Separation of Ligand-Activated Enhancers Licenses Cooperative Chromosomal Enhancer Assembly Researchers report that in human breast cancer cells, the acute 17β-estradiol-dependent activation of functional enhancers required assembly of an enhancer RNA-dependent ribonucleoprotein complex exhibiting properties of phase-separated condensates. [Nat Struct Mol Biol] Abstract Genome-wide transcriptome analysis of human endogenous retroviruses revealed that a primate long noncoding RNA, which scientists dubbed TROJAN, was highly expressed in human triple-negative breast cancer (TNBC). TROJAN promoted TNBC proliferation and invasion and indicated poor patient outcomes. [Sci Adv] Full Article Investigators revealed that the competitive endogenous RNA (ceRNA) network mediated by CYP4Z1 and CYP4Z2P (ceRNET_CC) promoted the stemness of breast cancer cells. Mechanistically, six2 activated ceRNET_CC by directly binding to their promoters, thus activating the downstream PI3K/Akt and ERK1/2 pathways. [J Hematol Oncol] Full Article miR-1271 suppressed breast cancer progression and epithelial-mesenchymal transition (EMT) phenotype both in vitro and in vivo by targeting SNAI2. Estrogen reversed transforming growth factor-β-induced EMT in a miR-1271 dependent manner. [J Exp Clin Cancer Res] Full Article Intronic DNA methylation was strongly associated with the overexpression of chromobox 2 (CBX2), an oncogene candidate that was identified using the authors’ method but not through prior analytical approaches. CBX2 overexpression in breast tumors was associated with the upregulation of genes involved in cell cycle progression and with poorer five-year survival. [Br J Cancer] Full Article Researchers showed that DCAC50, a recently developed small molecule inhibitor of the intracellular copper chaperones, ATOX1 and CCS, reduced cell proliferation and elevated oxidative stress, triggering apoptosis in a panel of triple negative breast cancer cells. [Mol Cancer Ther] Abstract | Full Article Scientists investigated the effect of SOX8 on tumorigenicity, migration and apoptosis in triple-negative breast cancer (TNBC) cell lines and xenografts models. They identified SOX8 as a functional oncogene involved in the maintenance of stem-like capacities in TNBC cells. [Carcinogenesis] Abstract Depletion of NLRX1 expression in triple-negative breast cancer cells altered the organization and activity of oxidative phosphorylation complexes in presence of TNF-α. NLRX1 depletion further impaired lysosomal function and hence the turnover of damaged mitochondria through mitophagy in presence of TNF-α. [Biochim Biophys Acta Mol Basis Dis] Abstract | Graphical Abstract 266 monoclonal antibodies (mAbs) demonstrated to interact with a wide variety of membrane, secreted and matrix proteins, were screened for their capacity to block tumorigenic cell-specific behaviors in a 3D environment. Only six of the 266 tested mAbs exhibited blocking activity, four targeting integrin ß-1, one targeting integrin α-3 and one targeting CD44. [MAbs] Abstract The clinical significance of SNHG6 expression in breast cancer was investigated. The authors found that the expression of SNHG6 was significantly upregulated in primary high-grade and progesterone receptor-positive breast tumors. [Cell Oncol (Dordr)] Abstract Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News. | |
| |
REVIEWSAndrogen Receptor: A Promising Therapeutic Target in Breast Cancer Investigators address the importance of the androgen receptor (AR) in breast cancer (BCa) diagnosis and prognosis, current AR-targeting approaches in BCa, and the potential for AR-downstream molecules to serve as therapeutic targets. [Crit Rev Clin Lab Sci] Abstract Visit our reviews page to see a complete list of reviews in the mammary cell research field. | |
| |
SCIENCE NEWSCyclacel Announces Abstracts Selected for Presentation Cyclacel Pharmaceuticals, Inc. announced that an abstract highlighting clinical data for Cyclacel’s DNA damage response program featuring sapacitabine in patients with breast cancer and an abstract reporting preclinical data for Cyclacel’s CYC065, have been selected for poster presentations. [Press release from Cyclacel Pharmaceuticals, Inc. discussing research to be presented at the American Association for Cancer Research (AACR) Annual Meeting 2019, Atlanta] Press Release Sermonix Pharmaceuticals LLC announced it will present a poster on the performance of its lead investigational drug, lasofoxifene. The abstract, “Lasofoxifene Achieves Potent Anti-Tumor Activity in Y537S ESR1 Hormone-Resistant Breast Cancer Cells by Saturating ERα,” will be presented. [Press release from Sermonix Pharmaceuticals LLC (GlobeNewswire, Inc.) discussing research to be presented at the annual meeting of the Endocrine Society (ENDO) 2019, New Orleans] Press Release SELLAS Life Sciences Group, Inc. announced final results from the efficacy and safety data analysis of the prospective, randomized, single-blinded, controlled Phase IIb independent investigator-sponsored clinical trial of the combination of trastuzumab +/- nelipepimut-S targeting HER2 low-expressing breast cancer patient cohorts, including triple-negative breast cancer patients. [Press release from SELLAS Life Sciences Group, Inc. discussing research presented at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium, San Francisco] Press Release | |
| |
INDUSTRY NEWSSTEMCELL Technologies Wins Deloitte Best Managed Companies Award STEMCELL Technologies announced that the company has been selected as a winner of Canada’s Best Managed Companies program for 2019. Canada’s Best Managed Companies is the country’s leading business awards program, recognizing excellence in the management abilities and practices of Canadian owned and managed companies with revenues over $15 million. [STEMCELL Technologies, Inc.] Press Release AstraZeneca and MSD, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending the use of Lynparza tablets as monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. [AstraZeneca] Press Release | |
| |
POLICY NEWSHead of US Food and Drug Agency Resigns Scott Gottlieb, the head of the US Food and Drug Administration (FDA), resigned on 5 March and will depart the agency in one month. [Nature News] Editorial | Opinion China Creating National Medical Ethics Committee to Oversee High-Risk Clinical Trials A powerful new national medical ethics committee, which will approve all clinical trials involving high-risk biomedical technologies, is at the center of a regulatory shakeup Chinese authorities are planning in the aftermath of the widely condemned “CRISPR babies” experiment, STAT has learned. [STAT News] Editorial
| |
EVENTSNEW Gordon Research Seminar: Overcoming Endocrine Resistance and Metastasis in Hormone-Dependent Cancers Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESPostdoctoral Associate – Cancer Immunology (The Jackson Laboratory) Scientific Review Officer – Breast Cancer (METAvivor) Faculty Position – Breast Cancer Research (The Mayo Clinic) Postdoctoral Fellow – Cancer Bioinformatics (BC Cancer Research Center, PHSA) Postdoctoral Fellowship – Breast Cancer (Providence John Wayne Cancer Institute) International Scientific Director – Breast Cancer (Roche) Postdoctoral Fellowship – Breast Cancer (Cold Spring Harbor Laboratory) Postdoctoral Fellowship – Cancer Research (North Carolina Central University) Postdoctoral Fellow – Breast Cancer Research (City of Hope) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Mammary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|